Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$5.45 USD
-0.03 (-0.55%)
Updated May 17, 2024 04:00 PM ET
After-Market: $5.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 1 - 20 ( 221 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dual MDS/AML Data Updates in 24 Hold Potential Positive Inflection Points; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SELECT-AML-1 Triplet Combination Update Is Supportive of Phase 3 Start
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimistic Ahead of SELECT-AML-1 Update in December 23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SELECT-AML-1 Data in 4Q23, With SELECTMDS- 1 Pivotal CR Data in 3Q24; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tamibarotene Continues to Improve its Position in AML and MDS; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SELECT-AML-1 Data in 4Q23, Remains The Key Inflection Point; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive SELECT-AML-1 During ASH 22 Bodes Well for Future Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimistic On SELECT-AML-1s Data During ASH 22; Reit. Buy and Raising Our PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Merger with TYME Technologies + PIPE, Recharges Syros Pipeline; Reit Buy and Lowering our PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 Update - Three Important Derisking Catalysts Expected in 2H2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Data Rich 2H22 Should Counterbalance Pipeline De- Prioritizations; Reit Buy and Lower PT to $10 From $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Catalysts Speak to Long-Term Growth Potential for Tamibarotene and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Updates - Key Readouts and Study Initiations in 2022, Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Key Clinical Catalysts Expected in 2022 Across Entire Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z